Zimmer Biomet Holdings, Inc. v. Mary Insall

108 F.4th 512
Court of Appeals for the Seventh Circuit·Decided July 12, 2024·No. 23-1888·Published·Cited by 4 cases

Opinion

In the

United States Court of Appeals For the Seventh Circuit

No. 23-1888 ZIMMER BIOMET HOLDINGS, INC., Plaintiff-Appellant,

v.

MARY N. INSALL, as Executrix of the Estate of John N. Insall, Defendant-Appellee.

Appeal from the United States District Court for the Northern District of Illinois, Eastern Division. No. 1:22-cv-02575 — Lindsay C. Jenkins, Judge.

ARGUED JANUARY 19, 2024 — DECIDED JULY 12, 2024

Before ST. EVE, LEE, and PRYOR, Circuit Judges. LEE, Circuit Judge. Dr. John Insall, an orthopedic surgeon who specialized in knee reconstruction and replacement, developed and obtained a number of valuable foreign and domestic patents involving knee replacement devices and accoutrements that he licensed to Zimmer Biomet Holdings, Inc. In exchange, Zimmer agreed to pay substantial royalties to Insall (which, upon his death, Zimmer paid to his Estate). After Insall’s last patent expired in 2018, Zimmer stopped all 2 No. 23-1888

royalty payments, asserting that its obligation under the royalty agreement had expired. The parties submitted the dispute to arbitration as required by the agreement, and the Estate prevailed. Zimmer then asked the district court to vacate the arbitration award, arguing that enforcement of the contract would violate public policy. The district court rejected this argument and confirmed the award. We agree and affirm.

I. Factual Background As a medical device company, Zimmer manufactures a variety of products, including technology used for knee replacements . Zimmer joined forces with Insall in 1991 to develop certain knee replacement devices and related appurtenances ultimately sold under the brand name “NexGen.” Under this plan, Insall would develop and secure patents for these devices , and Zimmer would pay royalties to Insall for the right to license, market, and sell them. This arrangement was memorialized in a written agreement in 1991. It required Zimmer to make royalty payments to Insall until “the expiration of the last to expire of the patents licensed hereunder or so long as Product is sold by ZIMMER, whichever is last to occur.”

The parties amended the agreement in 1994. Among other things, Insall promised to work exclusively for Zimmer through January 1, 2011. The parties also agreed to expand the scope of the agreement from the particular knee replacement system identified in the 1991 agreement to “the design and development of all components of any future knee system that is developed in whole or in part in the United States and offered as a standard line product for Zimmer.” As for the royalty payments, they were to encompass Insall’s work on “future knee systems” until “the expiration of the last to expire of the Patents licensed hereunder or on January 1, 2011,

No. 23-1888 3

whichever is last to occur.” The parties also added an arbitration provision that required all disputes arising out of or related to the agreement to be submitted for binding arbitration.

Portions of the agreement were amended again in 1998. Relevant here, the amended agreement provided:

The parties acknowledge that … royalties shall be paid at the rate of 1% of Net Sales Price on all sales of the NexGen Knee and all subsequently developed articles, devices or components marketed by Zimmer as part of the NexGen Knee family of knee components and not at the rate provided for sales of “future knee systems.”

In a previous arbitration between the parties (referred to as the Persona Arbitration, named after the technology at issue in that dispute), Zimmer’s counsel explained that the 1998 amendments changed the method by which royalties were to be calculated. Rather than being based on the sale of products containing the patented technology, the royalties under the 1998 agreement were based on the sale of items that Zimmer marketed under its “NexGen Knee” family of products. The arbitration provision remained unchanged.

Insall’s last patent expired on March 10, 2018, and Zimmer ’s chief patent counsel informed the Estate a few months later that the company would no longer pay royalties to the Estate. By way of explanation, Zimmer asserted that under the Supreme Court decisions Brulotte v. Thys Co., 379 U.S. 29 (1964), and Kimble v. Marvel Entertainment, LLC, 576 U.S. 446 (2015), a licensor may not collect royalties based on an expired patent. In its view, the payment of ongoing royalties under 4 No. 23-1888

the amended agreement ran “counter to the policy and purpose of patent laws.”

Unsurprisingly, the Estate disagreed, and the parties submitted the dispute for arbitration in late 2019. In a detailed decision, the arbitration panel concluded that Brulotte did not render the royalty provision in the 1998 agreement void and unenforceable. As such, the panel found that Zimmer had breached its obligations to pay royalties to the Estate, ordered Zimmer to pay past-due royalties, and affirmed Zimmer’s obligation to pay royalties to the Estate in accordance with the 1998 agreement.

Zimmer then initiated this lawsuit and asked the district court to vacate the award. The Estate responded with a motion to dismiss and moved the district court to confirm the arbitration award. The district court agreed with the Estate and confirmed the arbitration award. This appeal followed.

II. Scope of Review A. Standard of Review We review a district court’s decision on a motion to vacate or confirm an arbitration award under the Federal Arbitration Act (FAA) de novo. Webster v. A.T. Kearney, Inc., 507 F.3d 568, 571 (7th Cir. 2007). Factual findings are reviewed for clear error . Kinsella v. Baker Hughes Oilfield Operations, LLC, 66 F.4th 1099, 1103 (7th Cir. 2023).

We begin by emphasizing that the FAA and Supreme Court precedent establish that “arbitration awards are largely immune from … scrutiny in court.” Nano Gas Techs., Inc. v. Roe, 31 F.4th 1028, 1031 (7th Cir. 2022) (cleaned up). The breadth of our review is “extremely limited.” Chrysler Motors Corp. v. Int’l Union, Allied Indus. Workers of Am., AFL-CIO, 959

No. 23-1888 5

F.2d 685, 687 (7th Cir. 1992). We may not reconsider the merits of an award even when a party argues that the arbitrators made a factual error or even a legal one when interpreting a contract. United Paperworkers Int’l Union, AFL-CIO v. Misco, Inc., 484 U.S. 29, 36 (1987).

There is, however, a narrow exception to our tightly proscribed review. As discussed more below, “[t]he public policy doctrine allows this court to decide de novo whether [the award at issue] violates public policy.” Chrysler Motors, 959 F.2d at 687 (cleaned up).

B. The Federal Arbitration Act Arbitration aims to resolve disputes more efficiently and at a lower cost than traditional litigation. See Sarah Rudolph Cole, Curbing the Runaway Arbitrator in Commercial Arbitration: Making Exceeding the Powers Count, 68 Ala. L. Rev. 179, 184 (2016). In exchange for expediency and finality, however, parties trade the right to challenge the substance of the decisionmaker ’s ruling; as a result, judicial review of arbitral awards is extremely limited and highly deferential. See Affymax, Inc. v. Ortho-McNeil-Janssen Pharms., Inc., 660 F.3d 281, 285 (7th Cir. 2011) (citing Major League Baseball Players Ass’n v. Garvey, 532 U.S. 504 (2001)).

The FAA authorizes a court to vacate an award for only four reasons:

(1) where the award was procured by corruption , fraud, or undue means; (2) where there was evident partiality or corruption in the arbitrators, or either of them;

6 No. 23-1888

(3) where the arbitrators were guilty of misconduct in refusing to postpone the hearing, upon sufficient cause shown, or in refusing to hear evidence pertinent and material to the controversy ; or of any other misbehavior by which the rights of any party have been prejudiced; or (4) where the arbitrators exceeded their powers, or so imperfectly executed them that a mutual, final, and definite award upon the subject matter submitted was not made.

9 U.S.C. § 10(a).

Free access — add to your briefcase to read the full text and ask questions with AI

Zimmer Biomet Holdings, Inc. v. Mary Insall, 108 F.4th 512 (7th Cir. 2024).

108 F.4th 512 (Zimmer Biomet Holdings, Inc. v. Mary Insall) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related